公开(公告)号：US11801237B2

公开(公告)日：2023-10-31

申请号：US18314348

申请日：2023-05-09

申请人： Deciphera Pharmaceuticals, LLC

发明人： Michael D. Kaufman ,  Scott Bone ,  Corey Bloom ,  Fred Jordan

IPC分类号： A61K9/20 ,  A61K31/4375 ,  A61K9/16

CPC分类号： A61K31/4375 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2077

摘要： Provided herein is an amorphous compound represented by Formula (I):




and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof.

公开(公告)号：US20230310315A1

公开(公告)日：2023-10-05

申请号：US18022638

申请日：2021-08-31

申请人： PHILIP MORRIS PRODUCTS S.A.

发明人： Fabiana Spadaro ,  Gérard Zuber

IPC分类号： A61K9/00 ,  A61K31/444 ,  A61K9/16

CPC分类号： A61K9/0075 ,  A61K31/444 ,  A61K9/1623

摘要： An inhalable powder includes crystalline dry powder particles. The crystalline dry powder particles include a solid salt of an alkaloid and a sugar alcohol. The salt is solid at 25° C. The sugar alcohol may include mannitol, erythritol, myo-inositol, adonitol, xylitol, or a combination thereof. The inhalable powder may be part of a powder system that further includes a second population of particles having a particle size greater than that of the crystalline dry powder particles.

公开(公告)号：US20230303492A1

公开(公告)日：2023-09-28

申请号：US18199812

申请日：2023-05-19

申请人： THERAVANCE BIOPHARMA R&D IP, LLC

发明人： Grahame WOOLLAM

IPC分类号： C07D211/62 ,  C07D401/12 ,  A61K9/12 ,  A61K31/4545 ,  A61K45/06 ,  A61K9/16

CPC分类号： C07D211/62 ,  C07D401/12 ,  A61K9/124 ,  A61K31/4545 ,  A61K45/06 ,  A61K9/1623 ,  C07B2200/13

摘要： The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.

公开(公告)号：US20230301919A1

公开(公告)日：2023-09-28

申请号：US18022795

申请日：2021-08-31

申请人： PHILIP MORRIS PRODUCTS S.A.

发明人： Fabiana Spadaro ,  Gérard Zuber

IPC分类号： A61K9/16 ,  A61K9/19 ,  A61K31/465 ,  A61K31/444

CPC分类号： A61K9/1623 ,  A61K9/19 ,  A61K9/1694 ,  A61K31/465 ,  A61K31/444

摘要： A method of forming an inhalable powder composition including combining sugar or a sugar alcohol with an active agent and a liquid carrier to form a liquid mixture, and freeze drying the liquid mixture to form crystalline dry composition, and then milling the crystalline dry composition to from crystalline dry powder particles having a particle size of about 5 micrometers or less.

公开(公告)号：US11737991B2

公开(公告)日：2023-08-29

申请号：US17121547

申请日：2020-12-14

申请人： TONIX PHARMA HOLDINGS LIMITED

发明人： Marino Nebuloni ,  Patrizia Colombo

IPC分类号： A61K31/135 ,  A61K31/047 ,  A61K31/137 ,  A61K9/14 ,  A61K9/16 ,  A61K47/10 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K31/55

CPC分类号： A61K31/135 ,  A61K9/145 ,  A61K9/1623 ,  A61K9/1688 ,  A61K9/1694 ,  A61K31/047 ,  A61K31/137 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K31/55 ,  A61K31/137 ,  A61K2300/00 ,  A61K31/047 ,  A61K2300/00 ,  A61K31/135 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.

公开(公告)号：US20230248731A1

公开(公告)日：2023-08-10

申请号：US18188973

申请日：2023-03-23

申请人： NANJING GRITPHARMA CO., LTD.

发明人： Hongyan HE ,  Jiannan Yang ,  Yazhou He ,  Yizhang Zuo ,  Ruju Xiong ,  Jinling Li ,  Xiaotao Wu ,  Liru Huo ,  Zhan Li

IPC分类号： A61K31/519 ,  A61K9/16

CPC分类号： A61K31/519 ,  A61K9/1611 ,  A61K9/1623 ,  A61K9/1652

摘要： The present invention discloses a composition of palbociclib isethionate and a medicament, and belongs to the technical field of pharmaceutical preparations. The composition includes palbociclib isethionate, a diluent, a disintegrant and a lubricant, as well as optionally a glidant. The palbociclib isethionate in the composition has a release rate of greater than or equal to 60% at a pH of 6.8 at 60 min. According to technical solutions of the present invention, influence of the pH environment in the human body on the release of a palbociclib isethionate medicament is reduced, the restriction that a medicament needs to be taken after a meal is overcome, and the medicament prepared from the composition of palbociclib isethionate can be taken before or after a meal without the restriction of achieving different effects when the medicament is taken before or after a meal.

公开(公告)号：US20230233459A1

公开(公告)日：2023-07-27

申请号：US18008793

申请日：2021-05-28

申请人： PHILIP MORRIS PRODUCTS S.A.

发明人： Fabiana Spadaro ,  Gérard Zuber

IPC分类号： A61K9/00 ,  A61K31/452 ,  A61K9/16

CPC分类号： A61K9/0075 ,  A61K9/1623 ,  A61K9/1694 ,  A61K31/452

摘要： Anatabine powder compositions include a sugar or adhesion reducing compound and are suitable for inhalation and methods of forming the same. Sugar and an anatabine compound may be spray dried to form a dry anatabine powder composition. The anatabine powder may have a particle size of about 20 micrometres or less, 10 micrometres or less, or from about 1 to about 4 micrometres, measured as mass medium aerodynamic diameter. A powder may include a plurality of particles comprising an anatabine compound and a sugar or adhesion reducing compound and the plurality of particles have a particle size of about 20 micrometres to about 200 micrometres, measured as mass medium aerodynamic diameter.

公开(公告)号：US20230226099A1

公开(公告)日：2023-07-20

申请号：US17917346

申请日：2021-04-07

申请人： AALTO UNIVERSITY FOUNDATION SR

发明人： Christopher JONKERGOUW ,  Nurcin UGUR ,  Markus LINDER ,  Janne RAULA ,  Esko KAUPPINEN ,  Ekaterina OSMEKHINA

IPC分类号： A61K31/724 ,  A61K31/407 ,  A61K31/7036 ,  A61K31/5383 ,  A61K9/00 ,  A61K9/16 ,  A61P31/04

CPC分类号： A61K31/724 ,  A61K31/407 ,  A61K31/7036 ,  A61K31/5383 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/1623 ,  A61P31/04

摘要： This invention relates to inhalable formulation comprising a macrocyclic, cavity-containing compound as a biologically active ingredient. The present invention relates also to an inhalable formulation comprising a macrocyclic, cavity-containing compound as a biologically active ingredient for use in a method of treating an infection in a subject. In addition, the present invention relates to a method of treating an infection in a subject by administering an inhalable formulation comprising a macrocyclic, cavity-containing compound as a biologically active ingredient to the subject. The inhalable formulation comprising a macrocyclic, cavity-containing compound as a biologically active ingredient is suitable for the treatment of pulmonary or systemic infections caused by Gram-positive or Gram-negative bacteria.

公开(公告)号：US20230190659A1

公开(公告)日：2023-06-22

申请号：US18106193

申请日：2023-02-06

申请人： Iterion Therapeutics, Inc.

发明人： Gowri Sukumar ,  Drazen Ostovic

IPC分类号： A61K9/19 ,  A61K9/16 ,  A61K31/4545

CPC分类号： A61K9/19 ,  A61K9/1641 ,  A61K31/4545 ,  A61K9/1623

摘要： Formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.

公开(公告)号：US20230181472A1

公开(公告)日：2023-06-15

申请号：US17283068

申请日：2019-10-29

申请人： Amgen Inc.

发明人： Neil Obrad MACPHAIL ,  Angela Marie OLSOFSKY ,  Tiffany Lee THIEL ,  Yong XIE

IPC分类号： A61K9/16 ,  A61K31/55 ,  A61K9/20 ,  A61K9/28

CPC分类号： A61K9/1694 ,  A61K31/55 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/1617 ,  A61K9/1611 ,  A61K9/2018 ,  A61K9/2059 ,  A61K9/2013 ,  A61K9/2009 ,  A61K9/2095 ,  A61K9/2893 ,  A61K9/284

摘要： A new process for making ivabradine hydrochloride drug product reduces the amount of amorphous ivabradine hydrochloride in the drug product.